Boehringer capacity exceeds original forecast at new $809M Austrian plantnews2021-10-11T13:50:17+00:00October 11th, 2021|Fierce Pharma|
Timber posts data on topical Accutane, readies for pivotal trialnews2021-10-11T13:42:51+00:00October 11th, 2021|Fierce Pharma|
AbbVie’s Botox patent lawsuit is ‘very unlikely to derail’ Revance’s rival launch: analystsnews2021-10-11T13:32:04+00:00October 11th, 2021|Fierce Pharma|
Pfizer calls in the lawyers to block would-be rival to extended-release Xeljanznews2021-10-11T13:29:10+00:00October 11th, 2021|Fierce Pharma|
GlaxoSmithKline to leave landmark global HQ after split-up as consumer health business plots £120M new homenews2021-10-11T12:56:26+00:00October 11th, 2021|Fierce Pharma|
Jakafi maker Incyte channels blood testing anxiety in awareness adsnews2021-10-11T10:34:20+00:00October 11th, 2021|Fierce Pharma|
Entera advances oral challenger to Lilly’s Forteo, posting midphase data and heading to pivotal trialnews2021-10-11T10:11:57+00:00October 11th, 2021|Fierce Pharma|
Eli Lilly, Boehringer roll out video game for doctors to highlight cardio-renal-metabolic disease connectionsnews2021-10-08T16:05:20+00:00October 8th, 2021|Fierce Pharma|
Samsung Biologics speeds $2B plant build forecast to boost capacity 70%news2021-10-08T14:56:24+00:00October 8th, 2021|Fierce Pharma|
ChemoCentryx scores first FDA approval in 24-year history, and CEO Schall sees a blockbuster in the makingnews2021-10-08T14:35:12+00:00October 8th, 2021|Fierce Pharma|
